At the European Association for the Study of Diabetes (EASD) Annual Meeting 2026, three studies extended DFU management across the patient journey, from population risk identification to wound molecular features and systemic prognostic markers.
Article Key Points
- EHR analysis (~20,000 T2D, 6.29-yr follow-up): age, sex, obesity, smoking, prior CVD, renal decline predicted foot risk
- Neuropathy and absent pulses were the strongest DFU predictors (sHR ~2.2); eGFR G4-G5 and prior CVD also significant
- Wound proteomics (n=112): 27 proteins linked to healing time; S100A8, PGD, CORO1A tied to faster healing (HR 0.65-0.69)
- Urine ACR: 6-month composite adverse outcome 33.8% (normal) to 51.6% (severe); mortality 14.3% to 24.2% (p<0.02)
- Evidence status: conference abstracts; full results have not yet been peer-reviewed
Early Determinants: Foot Complications Risk Identifiable at T2D Diagnosis
Study design: Electronic health record analysis of approximately 20,000 individuals with newly diagnosed T2D in Tayside and Fife, Scotland, between 2008 and 2022. A Fine and Gray competing risk model (with death as the competing event) evaluated the prognostic value of clinical features in the first year after diagnosis for loss of protective sensation (LOPS), absent peripheral pulses, DFU, and amputation.
Results: Over a median 6.29-year follow-up, 2,783 LOPS, 1,372 absent pulse, 662 DFU, and 202 amputation events were observed, with 5,041 deaths. Age was the strongest predictor of neuropathic and vascular outcomes, with subdistribution hazard ratios (sHR) of approximately 2.0 in those aged 60-70 and 3.0-4.0 in those over 70 (versus <55 years, p<0.0001). Male sex (sHR ~1.3-1.5, p<0.01), grade II/III obesity (sHR ~1.2-1.6, p<0.0001, versus overweight), smoking (sHR ~1.1-1.4, p<0.05), and prior cardiovascular disease (CVD) (sHR ~1.4-1.8, p<0.0001) were each associated with elevated risk. All HbA1c values ≥53 mmol/mol (versus <53) were associated with elevated LOPS risk (sHR ~1.3), but only HbA1c 64-85 mmol/mol was associated with absent pulses. Renal function decline showed differential associations: KDIGO estimated glomerular filtration rate (eGFR) category G3 was associated with LOPS (sHR ~1.2, p<0.0001), while G3 and G4-G5 were both associated with absent pulses (sHR ~1.7, p<0.05).
For DFU, beyond male sex (sHR 1.3, 95% CI 1.1-1.6, p<0.001), the strongest associations were with established disease markers, including absent monofilament and pulses (sHR ~2.2), eGFR G4-G5 (sHR 1.9, 95% CI 1.1-3.3, p<0.001), and prior CVD (sHR 1.8, 95% CI 1.6-2.2, p<0.001). Amputation showed a similar pattern, but with fewer events and lower estimation precision.
These findings suggest that risk factors for foot complications can be identified at T2D diagnosis and that clinical neuropathic and vascular markers strongly predict subsequent ulceration, supporting early targeted prevention.
Wound Proteomics: Neutrophil-Driven Immune Signature Predicts DFU Healing
Study design: Proof-of-concept study of 112 patients with type 1 or type 2 diabetes and new-onset DFU. Wound surface swabs were collected, with 6-month follow-up or follow-up until ulcer healing. Liquid chromatography-mass spectrometry (LC-MS) was used for quantitative proteomics. Cox proportional hazards regression adjusted for clinical covariates was performed, with false discovery rate (FDR) p<0.2 as the significance threshold, complemented by multiple machine learning approaches.
Results: Mean participant age was 67.5 (SD 12.3) years, 62.5% had T2D, and 83.9% had peripheral neuropathy. After preprocessing, 256 proteins were retained, of which 27 were significantly associated with ulcer healing time (P_FDR<0.2). Functional enrichment analysis showed these proteins were primarily involved in antimicrobial defense, neutrophil degranulation, and leukocyte migration.
Top proteins associated with faster healing included S100A8 (hazard ratio [HR] 0.68), PGD (HR 0.65), and CORO1A (HR 0.69), whereas PSMA5 was associated with slower healing (HR 1.45). Causal mediation analysis suggested that the effect of faster-healing-associated proteins was partially mediated by triglyceride signaling. Neuropathic DFUs showed higher expression of neutrophil-derived innate immunity proteins, while neuroischemic ulcers showed intermediate expression, consistent with a pathophysiologic continuum. Machine learning analyses confirmed that these proteins were sufficient to distinguish healers from patients with chronic ulcers.
The study identified a neutrophil-driven innate immunity protein signature at the time of ulcer onset that stratifies DFU healing trajectories independently of diabetes type, while also reflecting ulcer etiology.
Urine ACR: A “Super Marker” for DFU Adverse Outcomes and Mortality
Study design: Cross-sectional analysis of 247 patients with new-onset DFU, stratified by baseline urine albumin-to-creatinine ratio (ACR) into normal (<30 mg/g, n=77), moderate albuminuria (30-300 mg/g, n=75), and severe albuminuria (>300 mg/g, n=95). The study evaluated the relationship between baseline ACR category and 6-month clinical outcomes, including wound healing, amputation, revascularization or angioplasty, death, and a composite adverse outcome (unhealed, amputation [any], death), adjusted for age, sex, and baseline HbA1c.
Results: Overall wound healing rates were moderate and similar across groups (29.9%, 25.3%, and 29.5%). Numerically, however, adverse outcomes trended upward with worsening albuminuria. Composite adverse outcome rates climbed from 33.8% in the normal ACR group to 48.0% in the moderate and 51.6% in the severe albuminuria group (trend test p<0.01). 6-month mortality rose with ACR (14.3% vs 26.7% vs 24.2%, p<0.02). Amputation (any) rates were similar across groups (p=ns), while revascularization procedures were slightly more common in severe ACR patients. Subgroup analysis suggested similar patterns across sex and glycemic control categories.
These findings suggest that elevated ACR is associated with increased risk of adverse 6-month outcomes in DFU patients, particularly composite adverse outcome and mortality. ACR may serve as a “super marker” of systemic disease severity in DFU, identifying patients at high risk of adverse outcomes.
Conclusion
Three studies advanced DFU management across the patient journey. At T2D diagnosis, age, obesity, smoking, CVD, renal function, and neurovascular markers identify high-risk individuals. Wound proteomics revealed a neutrophil-driven immune signature offering a non-invasive tool for predicting healing trajectories. Urine ACR emerged as a simple “super marker” for identifying patients at high risk of adverse outcomes and death. Future integration of these findings into clinical pathways could enable early prevention, individualized healing prediction, and risk-stratified management of DFU. Additional studies are needed to validate the clinical utility of these markers and to test whether targeted interventions can improve DFU outcomes.